Shares of Praxis Precision Medicines, Inc. (PRAX) plummeted 5.4% in pre-market trading on Thursday, following the company's release of its fourth quarter 2024 earnings results and financial update on Wednesday evening.
According to the earnings report, Praxis Precision Medicines reported weaker-than-expected revenue and wider losses for the quarter, missing analysts' estimates. The company also provided a gloomy outlook for its drug pipeline and clinical trial progress, citing delays and setbacks in some of its key programs.
The disappointing financial performance and bleak outlook appear to have rattled investors, leading to the significant sell-off in PRAX stock. Analysts warn that the company may face challenges in raising additional capital or securing partnerships if its drug development efforts continue to falter.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。